Sandner Sigrid E, Zimpfer Daniel, Zrunek Philipp, Rajek Angela, Schima Heinrich, Dunkler Daniela, Grimm Michael, Wolner Ernst, Wieselthaler Georg M
Department of Cardiothoracic Surgery, Medical University of Vienna, Vienna, Austria.
Ann Thorac Surg. 2009 Apr;87(4):1072-8. doi: 10.1016/j.athoracsur.2009.01.022.
Renal dysfunction as a risk factor with the use of left ventricular assist devices (LVAD) is controversial. We determined the effect of renal function on outcomes after continuous flow LVAD implantation.
Eighty-six patients with advanced heart failure undergoing continuous flow LVAD implantation as bridge to transplantation from November 1998 to July 2007 were retrospectively analyzed. Renal function was assessed using the Modification of Diet in Renal Disease study-derived glomerular filtration rates (GFR [mL x min(-1) x 1.73 m(-2)]). Patients were categorized into two groups based on pre-LVAD GFR: those with normal renal function (GFR > 60, n = 46), and those with renal dysfunction (GFR < 60, n = 40).
Post-LVAD survival at 1, 3, and 6 months for GFR greater than 60 was 91.3%, 79.9%, 72.6%, respectively, and for GFR less than 60, it was 92.5%, 66.5%, 47.9%, respectively (p = 0.038). Bridge-to-transplant rate was lower for GFR less than 60 than for GFR greater than 60 (40.0% versus 63.0%, p = 0.033). For GFR less than 60, GFR improved on LVAD support: implant to month 6, 41.7 +/- 11.5 to 62.7 +/- 25.0 (p = 0.021). Post-LVAD survival was improved in GFR less than 60 patients who after LVAD implantation recovered renal function to GFR greater than 60 (p < 0.001). Patients with post-LVAD renal failure had significantly lower post-LVAD survival regardless of pre-LVAD renal function (p < 0.001).
Patients with renal dysfunction have poorer outcomes after continuous flow LVAD implantation. However, renal function improves after LVAD implantation and is associated with improved survival. Our data underscore the importance of end-organ function in patient selection for LVAD therapy.
肾功能作为使用左心室辅助装置(LVAD)的一个风险因素存在争议。我们确定了肾功能对连续血流LVAD植入术后结局的影响。
回顾性分析了1998年11月至2007年7月期间86例因晚期心力衰竭接受连续血流LVAD植入作为移植桥梁的患者。使用肾脏病饮食改良研究得出的肾小球滤过率(GFR[mL×min⁻¹×1.73 m⁻²])评估肾功能。根据LVAD植入前的GFR将患者分为两组:肾功能正常组(GFR>60,n = 46)和肾功能不全组(GFR<60,n = 40)。
GFR大于60的患者LVAD植入后1个月、3个月和6个月的生存率分别为91.3%、79.9%、72.6%,而GFR小于60的患者分别为92.5%、66.5%、47.9%(p = 0.038)。GFR小于60的患者桥接移植率低于GFR大于60的患者(40.0%对63.0%,p = 0.0:3)。对于GFR小于60的患者,LVAD支持后GFR有所改善:植入至6个月时,从41.7±11.5升至62.7±25.0(p = 0.021)。LVAD植入后肾功能恢复至GFR大于60的GFR小于60的患者,其LVAD植入后的生存率有所提高(p<0.001)。无论LVAD植入前肾功能如何,LVAD植入后发生肾衰竭的患者LVAD植入后的生存率均显著降低(p<0.001)。
肾功能不全患者在连续血流LVAD植入术后结局较差。然而,LVAD植入后肾功能会改善,且与生存率提高相关。我们的数据强调了终末器官功能在LVAD治疗患者选择中的重要性。